ERBB2 and breast cancer: By comparison, the combination of HDACis with Exemestane in treating HR+/HER2- breast cancer can achieve an impressive ORR of up to 75%, establishing it as a potentially better choice for treatment in certain cases of HR+/HER2- breast cancer.